Impact of gender on the long-term outcome and survival of patients with autoimmune hepatitis

Al–Chalabi, Thawab; Underhill, James A.; Portmann, Bernard; McFarlane, Ian G.; Heneghan, Michael A.

doi:10.1016/j.jhep.2007.08.013

Cited by 159 publications

(146 citation statements)

References 27 publications

Supporting

Mentioning

123

Contrasting

Unclassified

Order By: Relevance

“…Interestingly, an examination of the long-term outcome of men with AIH attending King's College Hospital revealed more favorable outcomes generally among men when compared to women. 13 Although previous concerns have been raised regarding occult viral hepatitis (particularly HCV) infection as being instrumental in the etiology of HCC in AIH, all patients in this study were serologically negative for HBV and HCV infection. We also excluded all patients who had been described in a previous study from this unit by Ryder et al to avoid confusion with the current cohort.…”

Section: Discussionmentioning

confidence: 80%

Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: Implications for follow-up and screening

et al. 2008

Self Cite

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) has traditionally been considered a rare complication of cirrhosis secondary to autoimmune hepatitis (AIH), yet the true incidence remains unknown due to a lack of published data. Consequently, some professional guidelines do not mandate routine surveillance for HCC in this condition. Our aims were to evaluate the rate at which HCC develops among a large, prospectively obtained cohort of patients with AIH at a single center. Demographic, clinical, and laboratory indices associated with the development of HCC were also identified. HCC was discovered in 15 of 243 patients with AIH, all of whom had type 1 AIH equating to 1090 cases per 100,000 patient follow-up years. HCC occurred in the same proportion of females as males, 6.1% versus 6.4%, P ‫؍‬ 0.95. HCC occurred more frequently in patients who had cirrhosis at presentation, 9.3% versus 3.4%, P ‫؍‬ 0.048, or who had a variceal bleed as the index presentation of AIH, 20% versus 5.3%, P ‫؍‬ 0.003. The median duration from time of confirmed cirrhosis to a diagnosis of HCC was 102.5 months, range 12-195 months. Median survival in patients whose HCC was diagnosed on surveillance was 19 months (range 6-36 months) compared with 2 months (range 0-14 months) for patients presenting symptomatically (P ‫؍‬ 0.042). Conclusion: Cirrhosis in AIH is the sine qua non for HCC development, which subsequently occurs at a rate of 1.1% per year and affects men and women in equal proportions. (HEPATOLOGY 2008;48:863-870.)

show abstract

Section: Discussionmentioning

confidence: 80%

Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: Implications for follow-up and screening

et al. 2008

Self Cite

View full text Add to dashboard Cite

show abstract

“…The incidence rate is also different between men and women. It has been reported that women are more vulnerable to AIH [11]. Standard clinical therapy for AIH consists of a combination of corticosteroids and azathioprine and is the mainstay therapy for AIH [2].…”

Section: Introductionmentioning

confidence: 99%

Comparison of Concanavalin a-Induced Murine Autoimmune Hepatitis Models

Wang

Yang

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Autoimmune hepatitis (AIH) is a chronic necroinflammatory disease of the liver whose pathogenic mechanisms have not yet been elucidated. Moreover, the current treatment used for the vast majority of AIH patients is largely dependent on immunosuppressant administration and liver transplantation. However, research on the pathogenesis of AIH and effective new treatments for AIH have been hampered by a lack of animal models that accurately reproduce the human condition. Methods: AIH models created by concanavalin A (ConA) injections at different times and doses. The levels of ALT, AST, LDH and inflammatory cytokines were examined at various times after 20 mg/kg ConA was administered by ELISA using commercially available kits. Moreover, liver pathological changes were observed by flow cytometry (FCM) and H&E staining. Results: Our experiments demonstrated that the levels of ALT, AST, LDH and several inflammatory cytokines, including TNF-α, IFN-γ, and IL-6, were higher in the 20 mg/kg 12 h ConA group than in the other groups. Importantly, the numbers of activated CD4⁺ and CD8⁺ T lymphocytes in the blood, spleen and liver were calculated. These results showed that ConA (20 mg/kg for 12 h)-induced hepatitis was similar to that in clinical AIH patients. Furthermore, we found that the number of MDSCs in the blood was significantly increased in the ConA (20 mg/kg for 12 h) group compared with controls. Our findings indicated that ConA (20 mg/kg for 12 h)-induced hepatitis could be used as an experimental murine model that mirrors most of the pathogenic properties of human type I AIH. Conclusion: This model [ConA (20 mg/kg for 12 h)] provides a valuable tool for studying AIH immunopathogenesis and rapidly assessing novel therapeutic approaches.

show abstract

“…IgG-Spiegel finden sich in etwa 85 % der Patienten mit AIH [19], wobei von niedrigeren Präva-lenzen bei Patienten mit akuten Verlaufsformen berichtet wurde. So finden sich bei 25-39 % dieser Patientengruppe normale IgG-Spiegel [20].…”

Section: Klinikunclassified

Autoimmunhepatitis – Klinik, Diagnostik, Therapie

Stättermayer

Halilbasic

2018

J. Gastroenterol. Hepatol. Erkr.

View full text Add to dashboard Cite

Impact of gender on the long-term outcome and survival of patients with autoimmune hepatitis

Cited by 159 publications

References 27 publications

Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: Implications for follow-up and screening

Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: Implications for follow-up and screening

Comparison of Concanavalin a-Induced Murine Autoimmune Hepatitis Models

Autoimmunhepatitis – Klinik, Diagnostik, Therapie

Contact Info

Product

Resources

About